Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
Luana Colloca, Remo Panaccione, T.K. Murphy
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

The Nocebo Effect
Luana Colloca
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 171-190
Closed Access | Times Cited: 27
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Sizheng Steven Zhao, Laura Chadwick, Eduardo Mysler, et al.
Current Rheumatology Reports (2018) Vol. 20, Iss. 10
Open Access | Times Cited: 76
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 117-117
Open Access | Times Cited: 55
Switching Among Biosimilars: A Review of Clinical Evidence
Eleonora Allocati, Brian Godman, Marco Gobbi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 31
Risk factors associated with nocebo effects: A review of reviews
Francesca Grosso, Diletta Barbiani, Cesare Cavalera, et al.
Brain Behavior & Immunity - Health (2024) Vol. 38, pp. 100800-100800
Open Access | Times Cited: 7
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
Liese Barbier, Steven Simoens, Arnold G. Vulto, et al.
BioDrugs (2020) Vol. 34, Iss. 6, pp. 797-808
Open Access | Times Cited: 45
Evidence-based public policy making for medicines across countries: findings and implications for the future
Brian Godman, Joseph Fadare, Hye-Young Kwon, et al.
Journal of Comparative Effectiveness Research (2021) Vol. 10, Iss. 12, pp. 1019-1052
Open Access | Times Cited: 36
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
Brian Godman, Mainul Haque, Trudy Leong, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 34
Navigating adalimumab biosimilars: an expert opinion
Vered Abitbol, Salim Benkhalifa, Caroline Habauzit, et al.
Journal of Comparative Effectiveness Research (2023) Vol. 12, Iss. 11
Open Access | Times Cited: 14
Health-Related Quality of Life and Mental Health in Drug Hypersensitivity Reactions and Drug-Induced Anaphylaxis: A Systematic Review and Meta-Analysis
Matteo Martini, Mariateresa Di Taranto, Veronika Höfer, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 6, pp. 1876-1890
Closed Access | Times Cited: 13
Biosimilar Uptake: The Importance of Healthcare Provider Education
Sonia Oskouei, Andrew R. Kusmierczyk
Pharmaceutical Medicine (2021) Vol. 35, Iss. 4, pp. 215-224
Open Access | Times Cited: 30
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
Seenu M. Hariprasad, Richard Gale, Christina Y. Weng, et al.
Ophthalmology and Therapy (2022) Vol. 11, Iss. 3, pp. 959-982
Open Access | Times Cited: 22
Biosimilars
Maria Sheridan, Matthew Massich, Nazanin Ashourian
Journal of Infusion Nursing (2024) Vol. 47, Iss. 1, pp. 19-29
Open Access | Times Cited: 4
Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review
Neil M. Bressler, Peter K. Kaiser, V. Diana, et al.
Survey of Ophthalmology (2024) Vol. 69, Iss. 4, pp. 521-538
Open Access | Times Cited: 4
Evaluating the impact of changing inhaler color on perception of symptoms and disease burden in patients with asthma: The FEEL study
Francesco Blasi, Maria D'Amato, Vincenzo Patella, et al.
Journal of Asthma (2025), pp. 1-11
Closed Access
Cross-sectional patient survey of biological medicine users in Finland to investigate the types of guidance needed by patients in order to carry out their treatment successfully
Mari Pölkki, Tuire Prami
BMJ Open (2025) Vol. 15, Iss. 1, pp. e090136-e090136
Open Access
Transition from reference adalimumab to biosimilar SB5 in patients with rheumatoid arthritis: sub-analysis of Spanish patients in the PROPER study
Fernando Perez‐Ruiz, B Paret, Eugenio Chamizo Carmona
Exploration of Musculoskeletal Diseases (2025)
Closed Access
Awareness and Knowledge of Biosimilars Among Rheumatologists and Patients
Muhammad Shiraz Niaz, S M Syed Mohamed Suhail, Usama Mahmood
Journal of Health and Rehabilitation Research (2025) Vol. 5, Iss. 1, pp. 1-7
Closed Access
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review
Joshua A. Roth, Victoria W Dayer, Mireia Jofre‐Bonet, et al.
BioDrugs (2025)
Closed Access
ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology
Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, et al.
JCO Oncology Practice (2023) Vol. 19, Iss. 7, pp. 411-419
Open Access | Times Cited: 10
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region
Khalid A. Alnaqbi, Nasra Al Adhoubi, Sara Al Dallal, et al.
BioDrugs (2024) Vol. 38, Iss. 3, pp. 449-463
Open Access | Times Cited: 3
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
Zhen Zeng, Hao Lin, Mingshan Jiang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
Brian Godman, Mainul Haque, Santosh Kumar, et al.
Current Medical Research and Opinion (2021) Vol. 37, Iss. 9, pp. 1529-1545
Open Access | Times Cited: 20
Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments
Tomás Gabriel Bas, Vannessa Duarte
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 925-925
Open Access | Times Cited: 2
Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?
Ferdinando D’Amico, Virginia Solitano, Laurent Peyrin‐Biroulet, et al.
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 1, pp. 47-55
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top